

Massachusetts-based company to present positive clinical study of engineered virus to fight brain cancer

Auburndale, MA May 27, 2015 – Advantagene, Inc. announced today that results of its latest oncology research in malignant glioma will be presented during the Clinical Science Symposium "Immunotherapy for Central Nervous System Tumors: Biomarkers and Novel Data" on Sunday May 31, 8:00am (Abstract#2010) at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), in Chicago, Illinois (USA). Presentation of the Phase 2 GliAtak study by Dr. David S. Baskin, Kenneth R. Peak Brain & Pituitary Tumor Center Director at Houston Methodist Hospital, will include final analysis of overall survival. The results provide further insight on the potential for Advantagene's investigational Gene Mediated Cytotoxic Immunotherapy (GMCI®) technology, a multifunctional viral based biotherapeutic that targets stimulation of the patient's own immune system to recognize minimal residual disease and improve treatment outcomes.

About Advantagene, Inc.

Advantagene is a Massachusetts based biotechnology company developing its proprietary *Gene Mediated Cytotoxic Immunotherapy (GMCI®)* technology for the treatment of solid tumors. GMCI® is an "off the shelf" low toxicity immunotherapy that stimulates a patient's own immune system to generate a robust response against his or her cancer, causing tumor cell death and clearance. Advantagene is conducting a registration clinical trial with its lead clinical candidate, ProstAtak®, for the treatment of newly diagnosed prostate cancer patients under a Special Protocol Assessment issued by the U.S. Food and Drug Administration. If approved, ProstAtak® will be the first and only pharmaceutical intervention available for these patients. The company has additional Phase II and Phase I/II clinical studies using GMCI® to treat lung, pancreas and brain cancer with impressive clinical results to date.

For more information about Advantagene and our GMCI® cancer immunotherapy program please visit www.advantagene.com

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advantagene's plans and ability to develop its GMCI® technology to safely and effectively treat cancer. These forward-looking statements are subject to a number of risks. Advantagene undertakes no obligation to update these forward looking statement and you are cautioned not to place undue reliance on any of these forward-looking statements.